Castle Biosciences (US:CSTL) — Company Overview, News & Financial Data
Castle Biosciences develops diagnostic tests for cancers, focusing on skin cancer and precision oncology.
About Castle Biosciences
Castle Biosciences (NASDAQ:CSTL) specializes in developing and commercializing diagnostic and prognostic tests for cancers. They are devoted to transforming disease management through innovative molecular diagnostics that guide patient care. Their portfolio focuses chiefly on skin cancer, including melanoma, where they've made significant strides. Castle Biosciences aims to expand its impact by advancing the understanding of cancers at the genetic level, thus improving treatment decisions and outcomes for patients. Their objective is to lead in the realm of precision oncology, making personalized medicine more accessible and effective for cancer patients worldwide.
Snapshot
Operations
Products and/or services of Castle Biosciences
- DecisionDx-Melanoma, a diagnostic test predicting the risk of melanoma cancer spreading.
- DecisionDx-UM, a test to determine the risk of metastasis for uveal melanoma patients.
- DecisionDx-SCC, a genomic test for cutaneous squamous cell carcinoma prognosis.
- myPath Melanoma, a diagnostic tool distinguishing between benign moles and melanoma.
- DiffDx-Melanoma, aiding in the difficult diagnosis of melanoma versus benign skin lesions.
- TissueCypher, a Barrett's Esophagus test predicting progression to esophageal disease.
Castle Biosciences executive team
- Mr. Derek J. MaetzoldFounder, CEO, President & Director
- Mr. Frank StokesCFO & Treasurer
- Ms. Kristen M. Oelschlager R.N.Chief Operating Officer
- Mr. Tobin W. JuvenalChief Commercial Officer
- Ms. Camilla ZuckeroVice President of Investor Relations & Corporate Affairs
- Mr. Kevin DomanVice President of Sales
- Dr. Jay Braxton Pharm.D.VP of Marketing & Brand Manager of Uveal Melanoma (UM)
- Ms. Keli GreenbergVice President of Human Resources
- Dr. Matthew Goldberg M.D.Senior Vice President of Medical